Amaç: DR-70, kandaki fibrin yıkım ürünlerini tespit eden yeni geliştirilmiş bir testtir. Bu çalışmada ileri evre gastrointestinal (GI) kanserlerde DR- 70’in tedavi yanıtını izlemedeki etkinliğini değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmaya farklı serilerdeki sistemik tedaviler ile tedavi edilen ileri evre GI kanserli hastalar dahil edildi. Görüntüleme çalışmaları, DR-70 ve geleneksel tümör belirteçleri [karsinoembriyonik antijen (CEA), karbonhidrat antijeni (CA) 19-9] başlangıçta ve tedavinin üçüncü ayında tekrarlandı. Bulgular: Çalışmaya kolorektal (%52,1), özofagogastrik (%32,4) ve pankreatikobiliyer kanser (%15,5) tanısı konan toplam 142 hasta alındı. Hastaların çoğu birinci basamak tedavi alıyordu (%56,3). Hastaların %57’sinde ikinci kan örneği alındı. Özofagogastrik kanseri olan hastalarda, DR-70 yanıtı tedavi yanıtı ile iyi korelasyon gösterdi (p=0,007) ve başlangıçta düşük serum DR-70 düzeyi, daha uzun genel sağkalım ile anlamlı şekilde ilişkiliydi (p=0,02). Kolorektal kanserli hastalarda tedavi öncesi DR-70 ile CEA düzeyleri arasında pozitif fakat zayıf bir korelasyon (p=0,03, r=0,244) varken, tedavi öncesi DR-70 ile CA 19-9 arasında özofagogastrik ve pankreatikobilier kanserlerde orta düzeyde pozitif bir korelasyon vardı (sırasıyla p=0,01, r=0,402 ve p=0,04, r=0,515). DR-70 konsantrasyonunda %25’ten fazla azalma, daha iyi genel ve progresyonsuz sağkalım ile ilişkiliydi. Sonuç: DR-70, özellikle özofagogastrik kanserde tedaviye yanıtı ve sağkalımı ön gören güçlü bir belirteçtir.
Aim: DR-70 is a newly developed immunoassay that detects fibrin degradation products in blood. We aimed to evaluate ability of DR-70 in monitoring treatment response in advanced gastrointestinal (GI) cancers. Materials and Methods: We prospectively enrolled patients with advanced GI cancers treated with different lines of systemic therapies. Imaging studies, DR-70 and conventional tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9] were analyzed at baseline and on the third month of treatment. Results: A total of 142 patients diagnosed with colorectal (52.1%), esophago-gastric (32.4%) and pancreaticobiliary cancer (15.5%) were enrolled. Most patients were getting first-line treatment (56.3%). Second blood sampling was performed in 57% of patients. Among patients with esophagogastric cancer, DR-70 response correlated well with treatment response (p=0.007) and low baseline DR-70 level was significantly associated with longer overall survival (p=0.02). There was a positive but weak correlation between pre-treatment DR-70 and CEA levels (p=0.03, r=0.244) in patients with colorectal cancer, while a moderate positive correlation was present between pre-treatment DR-70 and CA 19-9 levels in esophagoAim: DR-70 is a newly developed immunoassay that detects fibrin degradation products in blood. We aimed to evaluate ability of DR-70 in monitoring treatment response in advanced gastrointestinal (GI) cancers. Materials and Methods: We prospectively enrolled patients with advanced GI cancers treated with different lines of systemic therapies. Imaging studies, DR-70 and conventional tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9] were analyzed at baseline and on the third month of treatment. Results: A total of 142 patients diagnosed with colorectal (52.1%), esophago-gastric (32.4%) and pancreaticobiliary cancer (15.5%) were enrolled. Most patients were getting first-line treatment (56.3%). Second blood sampling was performed in 57% of patients. Among patients with esophagogastric cancer, DR-70 response correlated well with treatment response (p=0.007) and low baseline DR-70 level was significantly associated with longer overall survival (p=0.02). There was a positive but weak correlation between pre-treatment DR-70 and CEA levels (p=0.03, r=0.244) in patients with colorectal cancer, while a moderate positive correlation was present between pre-treatment DR-70 and CA 19-9 levels in esophago-
